Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results

Stock Track06-01

Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.

The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).

Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128280885?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 15:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128280885","market":"us","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results","media":"Stock Track","content":"<p>Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.</p><p>The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).</p><p>Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-01 15:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.</p><p>The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).</p><p>Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1128280885","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128280885","pubTimestamp":1780299350,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"股票追踪|Summit Therapeutics因Ivonescimab肺癌试验结果积极飙升11.46%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128280885","isCrawlerRequest":true}